cabotegravir – Medxy AI

Long-Acting Injectable ART Superior to Oral Regimens in Patients with HIV Adherence Challenges: Insights from the LATITUDE Trial

By MedXY 02/22/2026

The LATITUDE trial reveals that monthly injectable cabotegravir-rilpivirine significantly reduces treatment failure compared to standard oral ART in individuals with HIV who struggle with daily medication adherence, potentially reshaping clinical guidelines for vulnerable patient populations.

Infectious Diseases news

Long‑acting Cabotegravir–Rilpivirine Achieves Durable Viral Suppression at 96 Weeks in African CARES Trial: A Practical Leap for HIV Treatment Delivery

By MedXY 11/13/2025

The CARES phase 3b trial in Africa found cabotegravir + rilpivirine long‑acting injections every 8 weeks noninferior to continued oral ART for viral suppression at 96 weeks, with an acceptable safety profile and implementation considerations for African programmes.